Zevra Therapeutics Gains Momentum With Miplyffa Approval and Market Expansion Potential in Rare Disease Treatment
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $20
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $25
Zevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy Rating
Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity